Pharma Leader Series: Top Generic Drug Producers - Leading Companies and Forecasts 2015-2025

LONDON, July 27, 2015 /PRNewswire/ --

Prospects for Development, Manufacturing and Business Expansion 

Generic Drug Producers - Discover Top Companies' Revenue Prospects Now, Benefiting Your Influence
What does the future hold for manufacturers and sellers of generic medicines? Visiongain's new report shows you leading companies' prospects to 2025. That study lets you discover results, trends, opportunities and revenue forecasts, helping you stay ahead in knowledge.

For leading producers and marketers of generic drugs, you find information on established and rising companies. Explore their sales potentials in the generics market, seeing from 2015 to 2025 the prospects of industry leaders. What revenues are possible?

Sales predictions and other data to help you stay ahead in competitive intelligence
In our study you find analytical profiles of top generics producers. By region you analyse historical data, activities, revenue forecasts and growth rates. Discover qualitative analysis too. That work gives you 82 tables, 87 charts and two interviews with the industry.

Our new analysis shows you the most lucrative parts of the world industry for generic drugs. See today how you can benefit your research, analyses, decisions, proposals and presentations, also saving time and benefiting your reputation for insight.

Assessments of top companies - capabilities, results, competition and sales potentials
Our report assesses 43 leading manufacturers of generic medicines worldwide. In general a company profile gives you the following information:

• Discussion of activities, technologies and recent financial results
• Assessment of developments - mergers and acquisitions (M&A), new products, outlooks, challenges and plans
• Forecasting of generic drug revenues to 2025 (for 19 leading companies).

Discover capabilities, progress and prospects of top generics companies, grouped by region, helping you stay ahead in commercial knowledge and influence. Our study explains the changing generics industry from 2015 to 2025, including opportunities.

For the top 50 generic drug manufacturers in 2014, discover revenues and rankings. Also see top companies' gross profit margins, EBITDA margins and historical revenue growth.

To see a report overview please email Sara Peerun on [email protected]

The following sections show how our new investigation helps your work.

North America - outlooks for leading generic drug producers and sellers
First our report analyses 13 North American generics specialists and big pharma companies in that market, including these firms:

• Mylan
• Pfizer
• Abbott
• Hospira
• Apotex
• Par Pharmaceuticals

In that analysis you find where revenue growth occurs and how high sales can go. Many opportunities remain, with high, expanding revenues possible from 2015.

Europe - prospects for leading generics players
Our survey also shows you outlooks for 10 European generics specialists and pharmaceutical leaders in that industry, including these firms:

• Novartis (Sandoz)
• Actavis
• Sanofi
• Fresenius Kabi
• Pharmstandard
• Gedeon Richter
• Stada Arzneimittel

The report shows you how companies can seize opportunities and expand their businesses from 2015 to 2025. You also examine organisations competing for shares of that expanding, evolving market.

India - analysis of leading generic drug firms
Our new work also assesses 10 Indian generic drug producers, including these firms:

• Sun Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Lupin
• Ranbaxy
• Aurobindo
• Glenmark
• Wockhardt

How much sales growth and geographical expansion can Indian generics companies achieve from 2015? Our study shows you revenue data, trends and prospects, examining what opportunities and potentials exist.

Producers from the rest of world - assess technologies, progress and prospects
Our investigation also shows you outlooks for 10 generic drug makers based in other countries, including these companies:

• Teva Pharmaceutical Industries
• EMS
• Aspen Pharmacare
• Nichi-Iko
• Abdi Ibrahim
• Hypermarcas
• Eurofarma
• Sawai Pharmaceuticals

Countries such as Japan, Brazil and China will become increasingly important for generic drug development, production and sales from 2015 to 2025, our analyses show.

That work explains forces shaping the generics market and industry, helping you explore changes, challenges and opportunities. Discover what the future holds.

Issues affecting generic drug development, manufacturing and sales
Our report discusses issues and events affecting that industry and market from 2015, including these forces:

• Specialty generics - difficult-to-produce medicines with high profit margins
• Shift towards innovative and improved drugs, via expanding R&D budgets
• Mergers and acquisitions (M&A) influencing that expanding healthcare market
• Big pharma firms targeting generics - diversification of product portfolios
• International expansion - targeting developed and developing national markets
• Intellectual property - regulations, challenges and developments
• Biosimilars - opportunities for generic and originator drug companies

There you explore the generic drug industry's strengths, weaknesses, opportunities and threats. With our study you discover what the future holds for top generic drug producers.

You also gain our interviews with Sanofi Generics and the Generic Pharmaceutical Association (GPhA). Hear what participants think, say and do, helping you stay ahead.

Ways Top Generic Drug Producers - Leading Companies and Forecasts 2015-2025  

- Prospects for Development, Manufacturing and Business Expansion helps
In particular, our new analysis benefits your work in these five main ways:

• Profiles of 43 generics companies - assess product ranges, strategies and sales results, also gaining revenue forecasts to 2025 for 19 organisations
• Competition and opportunities - explore what shapes the generic drugs market's future, especially companies' prospects for sustaining and expanding business
• Analysis of what benefits and restrains generic drug makers - assess challenges and strengths, helping you compete and gain advantages
• Reviews of established competitors and rising players in the generics sector - explore needs, competition, technologies and outlooks for future success
• Interviews with authorities - discover what participants in the industry think, say and do, helping you stay ahead in commercial knowledge.

That report, by visiongain's in-house analysts in the UK, gives information to benefit your work, saving you hassle and time. You gain data leading companies depend on.

Knowledge found nowhere else, helping your research, analyses and decisions
Our investigation gives independent analysis. You receive competitive intelligence found only in that report, discovering generics companies with the most commercial promise.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions. Also find how you can save time and gain in recognition for insight, benefiting your authority.

Predictions for generic drug production and sales - gain by trying our study now
Our new analysis shows you data, trends, opportunities and sales forecasts for top producers and sellers of generic drugs. Avoid missing out - please get our report here now.

To see a report overview please email Sara Peerun on [email protected]

Organisations Mentioned in the Report
Abbott
AbbVie
Abdi Ibrahim
Abrika Pharmaceuticals
Ache
Actavis
Active Pharma
Adcock Ingram
Advance Vision Research
Aegera
Afrexa Life Sciences
Agouron Pharmaceuticals
Akorn Pharmaceuticals
Akrikhin
Alcon
Allergan
Alpharma
Alvogen
AmerisourceBergen
Amide
Amneal Pharmaceuticals
AMS
APL Holdings Limited
ApoPharma
Apotex
Apotex Fermentation
APP Pharmaceuticals
Aprogen
Arrow Group
Asahi Kasei Pharma Corporation
Ascent Pharmahealth
ASKA Pharmaceutical
Aspen
Aspen Pharmacare
Aspen Trading  
AstraZeneca
Auden McKenzie
Aurigene Discovery Technologies
Auro Pharma
Aurobindo
Balkanpharma
Barr Pharmaceuticals
Bausch and Lomb Holdings
Bayer
Bayer Yakuhin
BeiKang Pharmaceutical
Bever
Biocad Holding
Bioniche Pharma
Biovena
Boca Pharmacal
Boehringer Ingelheim
Brainfarma Industria e Farmaceutica
Bremer Pharma    
Bunker and Delta
Cadila Healthcare
Cardinal Health
Cenova Pharma
CFR Pharmaceuticals
Chatted
Chattem Chemicals
Chimpharm
Chiron Corporation
Chirotech Technology
CIBA VISION
Cipla
CNS Therapeutics
Colotech
Cosmed Industria de Cosmeticos e Medicamentos S.A.
D. Searle & Company
Dabur Pharma
DACA Pharmaceuticals
Daichi Kasei
Dialfor Health
DKSH
Dr. Reddy's Laboratories
Dream Pharma
Dusa Pharmaceuticals
EBEWE Pharma
Elan Pharmaceuticals
Elder Pharmaceuticals
Emcure
Emergent Biosolutions
Emploi Quebec
European Medicines Agency
EMS
Endo
Eon Labs
Ethics Bio Lab
Eurofarma
Facet Biotech
Fako
Fenwal
Filaxis
Fougera Pharmaceuticals
Fresenius Kabi
Fuso Pharmaceutical Industries
Gangene Corp
Gedeon Richter
Generic Health  
Generic Pharmaceutical Association (GPhA)
Genfar S.A.
Genzyme
Germa Pharm
GlaxoSmithKline (GSK)
Glenmark
Globalpharma
Golden Cross Pharma
Greenstone
Handok
HealthTronics
Helvepharm
Herbapol Pruszkow
Hexa
Hikma
Hi-Tech Pharmacal
Hospira
Hypermarcas
IDEV Technologies
Ikaria
Innopharma
Inspire Pharmaceuticals
Investissement Quebec
Ipca Laboratories
J-DOLPH Pharmaceutical
Johnson & Johnson
JPH Group Holdings
Kanghong Sagen Pharmaceuticals
Keri Pharma
Kilitch Drugs
Kolmar Holdings
Krka
Kunwha Pharmaceuticals
Kyowa Pharmaceuticals
Labesfal
Laboratorio Sanderson
Laboratorios Gautier
Laboratorios Grin
Laboratorios Kendrick
Labormed Pharma
Leek
Lekko
Les Laboratoires Servier SAS
Lotus Pharmaceuticals
Lupin
mAbxience
Madaus
Mallinckrodt
Maruko Pharmaceutical
Masterlek
McKesson Drug Company
Mechnikov Biomed
Mediate Specialities
Medina
Medisa Shinyaku
Medley Industria Farmaceutica
Meiji Seika Pharma
Merck & Co
Microdose
Mitani Sangyo
Mitsubishi Tanabe Pharma
MJ Pharma
Multicare
Mylan Laboratories
Nanomi B.V
National Druggists  
NBZ Pharma Limited
Negma
Nichi-Iko
Nichi-Iko Pharma Tech
Nicox
Nippon Chemipher
Nippon Kayaku
NIXS Corporation
Novartis
Nycomed
Oak Pharmaceuticals
OctoPlus
Omega Laboratories Limited
Onset Dermatologics
Onyx
Oriel Therapeutics
Orion
Paladin Labs
Par Pharmaceutical
Parke-Davis
Pendopharm
Perrigo Company
Pfizer
PGT Healthcare
Pharma Avalanche
Pharmacin
Pharmapark
Pharmascience
Pharmascience Korea
PharmaSwiss
Pharmstandard
Pharmstandard Biotec
Phlox Pharma
Pinewood Laboratories
Piramal Healthcare Solutions
Polfa Warszawa
Polpharma
Pradeep Drug Company
Promius Pharma
Pymepharco
Qalitest
Questcor
Ranbaxy Laboratories
Ranbaxy Life Sciences Research
Ratiopharm
Ribbon
Richter-Helm
Roche
Romark Laboratories
Sabex
Sagent Acquisition Corp
Salix Pharmaceuticals
Sandoz
Sanofi
Sanofi Pasteur
Sawai Pharmaceuticals
Schein Pharmaceutical
Sekisui Medical
Shantha Biotechnics
Silom Medical Company
Sindan
Solus Pharmaceuticals
Solvay Pharmaceuticals
Somar
Specifar Pharmaceuticals S.A.
SPIL de Mexico
Spirig Pharma
Stada Arzneimittel
STARLIMS
Sun Pharmaceutical
Swisse Wellness
Taiyo  Cephalon
Taro
Technologies Inc
Teikoku Medix
Terapia S.A.
Teva Pharmaceutical Industries
The European Generic Medicines Association (EGA)
The Generic Pharmaceutical Association
TKS Pharmaceutical
Torrent Pharmaceuticals
Towa
UDL Laboratories
United Research Laboratories  
URL Pharma
US Food and Drug Administration (FDA)
Uteron Pharma S.A.
Valeant
Velefarm
Veropharm
VersaPharm Incorporated
Vindexpharm
VPI Holdings Corp
Warner Chilcott
Warner Lambert
Watson Pharmaceuticals
Winthrop
Wockhardt
Wyeth
Yakuhan Pharmaceuticals
ZAO Ranbaxy
Zao Sun Pharma
Zhejiang Chiral Medicine Chemicals Company
ZiO Zdorovje
Zoetis
Zydus Pharmaceuticals
Zydus Wellness

To request an exec summary of this report please email Sara Peerun at [email protected]
or call Tel: +44(0)20-7336-6100
Or click on https://goo.gl/hmzcPM

SOURCE Visiongain